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during eight individual cognitive interviews. ConClusions: The mixed-methods 
approach provides valuable support in the development of a fit-for-purpose instru-
ment assessing impacts of cLBP. Upon testing this revised PAL-I in a second pilot 
quantitative study, the final measure will undergo formal validation including sen-
sitivity to change.
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objeCtives: 1) To identify orphan medicines indicated for lymphoproliferative dis-
orders approved by the European Medicines Agency (EMA); (2) To identify medicines 
for which a PRO evaluation was performed; (3) To list those with a PRO labeling claim, 
and (4) To identify reasons for not granting a PRO claim. Methods: The search 
was performed on the EMA website (06/21/2014). The products were browsed by 
type (i. e., orphan medicines). Products refused and withdrawn were excluded. The 
PROLabels database was searched for each product retrieved to identify any PRO 
claim in the label. Summary of Product characteristics (SMPc) and CHMP Assessment 
Reports (AR) were retrieved for each product and analyzed to find out about PRO 
evaluation reported in the AR and not reported in the label. Results: Thirteen 
orphan medicines indicated in lymphoproliferative disorders were identified, rep-
resenting three main indications: lymphomas (Hodgkin, systemic anaplastic large 
cell, T-cell lymphoblastic, mantle-cell), leukemias (chronic lymphocytic, hairy cell, 
acute lymphoblastic) and multiple myeloma. Only one product had a PRO claim: 
ofatumumab (resolution of constitutional symptoms). The label of another product 
(brentuximab vedotin) indicated “resolution of B symptoms.” However, there was 
no mention in the AR on how the symptoms were collected (patient or clinician). 
For one product (pomalidomide), a HRQL evaluation was mentioned in the AR, but 
not reported in the label. However, there was no information about this evaluation 
in the AR and the reader is left to wonder about the HRQL results and the reasons 
for not including them in the label. ConClusions: The percentage of PRO claims 
in orphan medicines (7.7%) is inferior to the percentage of PRO claims in all EMA 
products (26%). This is remarkably low considering the profound effect of lym-
phoproliferative disorders on patients’ life. Efforts should be made to improve the 
reporting of PRO data in the CHMP Assessment Reports.
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objeCtives: Phenylketonuria (PKU) is a rare genetic disorder impacting pheny-
lalanine (Phe) metabolism. Treatment involves a lifelong Phe restricted diet that 
is strict and socially demanding. Even when treated early and well, mild cogni-
tive abnormalities have been seen. PKU can affect quality of life in individuals 
and their families. The phenylketonuria–quality of life (PKU-QOL) questionnaires 
are the first PKU-specific QOL questionnaires ever developed. The study aimed to 
perform the psychometric validation of these questionnaires. Methods: An obser-
vational study was conducted in France, Germany, Italy, The Netherlands, Spain, 
Turkey and the UK to finalize and validate PKU-QoL questionnaires in individuals 
with treated PKU aged 9–11, 12–17 and ≥ 18 years, and in parents of individuals < 18 
years. Questionnaires were assessed for reliability (internal consistency, test–retest), 
concurrent validity (using three generic questionnaires adapted to the respondent: 
PedsQOL, SF-36 for adults and CHQ-PF28) and clinical validity (using PKU severity 
and overall assessment of patient health status). Results: In total, 559 participants 
(306 individuals, ages 9–45 years; 253 parents, ages 24–66 years) were included in the 
analysis. Return rate and quality of completion of the questionnaires were good, 
indicating good acceptability. Scores were defined to assess all relevant aspects of 
experiences: PKU symptoms, impact of PKU, dietary protein restriction and sup-
plementation. Reliability and validity were satisfactory overall for the adolescent, 
adult and parent PKU-QoL questionnaires, and slightly weaker but acceptable for 
the child version. ConClusions: The four PKU-QOL questionnaires are valid and 
reliable instruments for assessing the specific quality of life aspects that are affected 
in individuals with PKU of different age groups (children, adolescents and adults) 
and their parents, and are available in seven languages. They are very promising 
tools for focused evaluation of PKU impact on individuals and parents in different 
countries, and for monitoring the efficacy of therapeutic strategies.
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objeCtives: Dengue infection is a major cause of disease in tropical areas with 
an estimated 50 million infections occurring each year and more than 2.5 billion 
people being at risk of infections. The main objective of this study was to investigate 
relation between white blood cells and platelets during recovery phase in dengue 
hemorrhagic fever. Methods: A retrospective multi-center study was conducted 
on 1000 seropositive cases of dengue fever. Results: More prevalence has been 
observed in male 880 (88%) as compared to female 120 (12%). A rapid fall in white 
blood cells count (WBC) was observed in initial CBC reports at start of disease then 
observational study. It was conducted from September 2011 to December 2012 and 
included a total of 1,109 patients who were scheduled for lumbar spinal surgery 
from 44 spinal centers (both orthopaedic surgery and neurosurgeons). Patients were 
diagnosed of having NP if the Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) pain scale criteria were ≥ 12 points. The patients were investigated 
to assess their pain severity using pain numeric rating scale (NRS) and quality 
of life using EuroQol (EQ)-5D at baseline, after 1 week and 3 months of the sur-
gery. Results: Among 1,109 patents, at baseline, NP was identified in 404 (36%) 
patients. After 1 week and 3 months of the surgery, NP was found in 8.6% and 
4.0% patients respectively. Among the 705 patients without NP preoperatively, the 
prevalence of de novo NP occurred in the 1 week and 3 months of post-surgery was 
3.1% and 2.3% respectively. At baseline, NP patients showed lower QoL compared 
with non-NP patients (0.49 vs 0.53 p< .001). However, NP patients improved more 
their QoL compared to non-NP patients after 3 months (0.86 vs 0.84 p=.029). Among 
the de novo NP patients at 3 months after surgery (n= 16), the pain severity was not 
improved after 1 week and 3 months of the surgery. ConClusions: In Korea, NP 
patients were suffered from severe pain and lower QoL than non-NP patients. De 
novo NP caused severe pain which may not easily be handled. Those study findings 
highlight that timely diagnosis and management of NP are required in patients 
with lumbar spine surgery.
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objeCtives: The Pain Assessment for Lower Back Symptoms (PAL-S) is a Patient 
Reported Outcome (PRO) instrument being developed to assess the key symptoms 
of chronic low back pain (cLBP). Qualitative development included both concept 
elicitation and cognitive interviews. As part of the ongoing development of the 
instrument, we further evaluated and refined the PAL-S using a mixed methods 
approach. Methods: Adults self-reporting a clinical diagnosis of cLBP were 
recruited from an existing US-based commercial survey panel to participate in 
a pilot quantitative study. Qualifying participants completed a web-based survey 
consisting of the 14-item PAL-S and items assessing clinical, treatment, and demo-
graphic characteristics. Study data was analyzed to assess item- and scale-level 
performance of the PAL-S using Rasch Measurement Theory analyses. Following 
analysis and modification, two waves of cognitive interviews were conducted to 
evaluate respondent understanding of the revised PAL-S. Results: The dataset 
included 598 respondents (mean age: 55.5±12.6; 67.9% female; 88.0% white; and 
54.0% married) who had cLBP for mean of 15.2±11.5 years. The Rasch analyses item 
threshold maps showed only two items having ordered thresholds, suggesting that 
respondents experienced increased difficulty distinguishing between options at 
the lower levels of the 0-10 scale. Simulations collapsing the responses to a best-
fit 4-point response scale resulted in improved ordering of thresholds, suggesting 
a more optimal response option structure. Based on these findings, the numeric 
response scale of the PAL-S items was replaced with a 4-point verbal rating scale 
incorporating response choices such as not at all, slight, moderate, and severe. Findings 
from eight cognitive interviews confirmed patient comprehension and relevance 
of the revised instrument. ConClusions: The mixed-methods approach proved 
valuable to the ongoing development of the PAL-S, as Rasch analyses identified 
a need for refinement of the response scale. The measurement properties of the 
revised PAL-S will be evaluated in additional web-based and clinic-based quantita-
tive studies.
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objeCtives: The Pain Assessment for Lower Back-Impacts (PAL-I) is a patient-
reported outcome (PRO) instrument being developed to assess key impacts, e. 
g. walking, sitting, standing, etc. associated with chronic low back pain (cLBP). 
Following a mixed methods approach, the PAL-I development included qualitative 
work (both concept elicitation and cognitive interviews) and now a quantitative 
“pilot study” evaluation for further content validity. Methods: Adults self-report-
ing a clinical diagnosis of cLBP were recruited from a US-based commercial survey 
panel. Qualifying participants completed a web-based survey consisting of the 
13-item PAL-I and items assessing clinical, treatment, and demographic character-
istics. Study data was analyzed to assess item- and scale-level performance of the 
PAL-I using Rasch Measurement Theory analyses. Following analysis and modifica-
tion, cognitive interviews were conducted to evaluate patient understanding of the 
revised PAL-I. Results: The 598 subjects in the pilot study reported having cLBP 
(mean of 6.1 on 11-point numerical rating scale, 0= no pain). Subjects experienced 
cLBP for 0.3 to 66 years (mean 15.2, SD 11.5), were 55.5 years old (SD 12.6), 67.9% 
female, 88.0% white and 54.0% married. The Rasch item threshold map showed 
only 2 items having an ordered threshold identifying problems with the response 
categories. Category probability curves indicated subjects had “difficulty” endorsing 
items specifically in relation to the extreme options. Based on these findings, four 
items were removed and the response options were modified for the remaining 
items (from 6-point scale 4-point: Not at all limited, Limited a little, Limited a lot, Did 
not do). Comprehension of the revised instrument was evaluated and confirmed 
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objeCtives: Rituximab SC reduces administration times (~5 minutes) com-
pared with the IV route (~4 hours). We examined the extent of patient prefer-
ence for rituximab SC versus IV in the PrefMab and MabCute studies using the 
Rituximab Administration Satisfaction Questionnaire (RASQ). Methods: In 
PrefMab (NCT01724021) patients with untreated CD20+ DLBCL/FL received 1 cycle 
of IV rituximab (375mg/m2) followed by either SC rituximab (1400mg, x3) then IV 
rituximab (x4), or IV rituximab (x3) then SC rituximab (x4), with chemotherapy. 
In MabCute (NCT01461928) patients with relapsed/refractory CD20+ indolent NHL 
received induction rituximab IV (375mg/m2; 1 cycle) then rituximab SC (1400mg; 
cycles 2–8) plus 6–8 chemotherapy cycles. RASQ evaluated preference by assessing 
patients’ perceptions of the impact of administration route and treatment satisfac-
tion. Conceptual validation of RASQ has been conducted and psychometric data 
will be reported. Results: Median RASQ scores for PrefMab were: convenience IV 
(n= 211) 58.3 (interquartile range: 41.7–75.0) and SC (n= 207) 83.3 (75.0–91.7); satisfac-
tion: IV (n= 211) 75.0 (62.5–87.5), SC (n= 208) 87.5 (75.0–100.0); impact on daily life: 
IV (n= 145) 50.0 (41.7–83.3), SC (n= 163) 83.3 (83.3–100.0); physical impact IV (n= 211) 
83.3 (66.7–100.0), SC (n= 208) 83.3 (75.0–100.0); psychological impact IV (n= 211) 80.0 
(65.0–90.0), SC (n= 208) 88.8 (75.0–95.0). SC administration was preferred by 80.3% 
and 85.9% of patients with IV or SC as most recent dose, respectively. Results were 
similar irrespective of treatment sequence. Median RASQ scores for MabCute 
(n= 92) were: convenience: IV 58.3 (33.3–66.7), SC 83.3 (66.7–83.3); satisfaction: IV 
62.5 (50.0–87.5), SC 87.5 (75.0–100.0); impact on daily life: IV 58.3 (41.7–66.7), SC 83.3 
(66.7–83.3); physical impact IV 75.0 (66.7–91.7), SC 83.3 (66.7–91.7); psychological 
impact IV 70.0 (60.0–85.0), SC 85.0 (75.0–95.0). ConClusions: Consistent patient 
satisfaction and preference for SC versus IV rituximab was demonstrated in the 
PrefMab and MabCute studies. RASQ is a reliable and valid measure of patient treat-
ment preference.
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objeCtives: We conducted a systematic literature review to identify published 
evidence from observational studies on the humanistic burden of multiple myeloma 
(MM). Methods: We searched MEDLINE, Embase, EconLit, and the Cochrane Library 
for English-language articles and analysed these qualitatively. Results: The review 
identified 20 publications based on 18 observational studies; these were mainly 
cross-sectional in design (n= 14). Most studies (n= 15) examined populations with 
MM in general, typically without stating the proportion with relapsed (R) or relapsed 
and refractory (RR) MM. Fewer studies examined patients with newly-diagnosed 
MM (n= 2) or RMM/RRMM (n= 1). Health-related quality of life (HRQoL) was typically 
assessed using validated cancer-specific instruments (e. g., the EORTC-QLQ-C30: 
n= 9; and the MM-specific EORTC-QLQ-MY20: n= 4). On average, patients with MM 
had poorer HRQoL compared to the general population (n= 6), and compared to 
patients with certain other hematologic cancers (n= 2). MM patients whose disease 
duration ranged from diagnosis to 11 years had greater physical function impair-
ment (p< 0.001) than other hematologic cancer patients. Other complaints included 
fatigue, bone pain, tingling, and non-specific pain. Patients on active treatment had 
worse side effects than those in a first treatment-free interval (p< 0.001); the latter 
had better scores on HRQoL dimensions including role and social function, future 
perspectives, and body image (all p< 0.05). Between baseline and one year, patients 
experienced worsening on the EORTC-QLQ-C30 global health scale (p< 0.001) and 
in fatigue, nausea/vomiting, and pain scores (all p< 0.05). Symptomatic patients 
had lower physical functioning scores (p< 0.05) than asymptomatic patients; those 
with severe symptoms had lower EORTC-QLQ-C30 global health scores (p< 0.05; 
mild/moderate symptoms: p= NS). Fatigue, bone pain, and anaemia were associated 
with lower. ConClusions: HRQoL in patients with MM deteriorates with disease 
duration, symptom severity, disease progression, or development of complications. 
This evidence suggests substantial unmet needs in MM patients.
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objeCtives: There are approximately 2,000 hemophilia patients in Korea, but 
patient-reported outcome (PRO) studies involving a large number of hemophilia 
patients have been rarely studied. The aim of this study was to assess PROs in 
moderate to severe hemophilia patients in Korea. Methods: It was a cross- 
sectional, multi-centered and observational study. Moderate to severe, male 
hemophilia patients aged 8 to 65 were recruited at 2 of Korea Hemophilia 
Foundations and 3 other pediatrics from November 2012 to September 2013. 
All patients completed self-reported questionnaires to measure patients’ char-
acteristics and PROs including health-related quality of life (HRQoL) and pro-
ductivity loss. HRQoL was examined using EQ-5D, ranged 0-1, which higher 
values indicate better HRQoL and Heamo-QoL, ranged 0-100, where higher val-
ues imply lower HRQoL. Productivity loss was estimated with absenteeism and 
presentism in terms of lost productivity time (LPT). Results: For a total of 605 
patients (mean age, 29.3 years; 88.6% with severe hemophilia) enrolled in this 
study, the mean scores of heamo-QoL and EQ-5D were 32.28 and 0.68 respec-
tively. The mean scores of EQ-5D in this study are comparable to 0.68 in rheu-
matoid arthritis patients from Korea Observational Study Network for Arthritis. 
Significantly lower EQ-5D was found in patients with the following clinical factors 
compared to those with reverse conditions; joint bleedings (0.68 vs. 0.73, p= .001), 
in platelet count. During recovery phase WBC count increased first followed by plate-
lets count production after 3-4 days. Among 1000 confirmed dengue fever patients 
812 were considered dengue hemorrhagic fever cases on the basis of clinical finding. 
In most of these cases (n= 783; 96.47%), directly proportional relation was observed 
between WBC and platelets count. ConClusions: It is wrongly perceived in com-
munity that dengue virus infection is still progressing when platelets count is below 
normal even the white blood cells counts is getting better during recovery phase. 
White blood cells production during recovery phase is a good indicator about recov-
ery of disease rather than focused on platelets counts production.
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objeCtives: To define the importance values assigned to the attributes of bio-
logical agents (BA) by Spanish rheumatologists and patients with rheumatic dis-
eases: rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis 
(PA). Methods: Observational, cross-sectional design based on conjoint analy-
sis. RA, AS and PA patients diagnosed at least 2 years prior and currently or pre-
viously (≤ 1 year ago) receiving BA for a minimum of 1 year were consecutively 
recruited. Rheumatologists with at least 3 year experience on BAs participated. A 
literature review and 4 focus groups were undertaken to identify attributes and 
levels. Scenarios were selected using orthogonal design. Participants ranked 8 
scenarios from 1 (most preferred) to 8 (least preferred). Relative importance (RI) 
of attributes was calculated. Multivariate regression analysis was performed for 
each attribute. Results: 488 patients [male= 50.9%; mean (SD) age= 50.6 (12.06) 
years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diagnosis= 12.6 (8.2) years] 
and 136 rheumatologists [male= 50.4%; mean age= 46.4 (9.1) years; mean time of 
practice= 16.7 (8.8) years] took part. Most important attributes selected by patients 
and physicians, respectively, were: ‘Pain relief and improvement of the functional 
capacity’ (RI= 49.1% and 48.9%); ‘Risk of adverse events’ (RI= 31.8% and 31.5%), 
‘Administration method’ (RI= 10.2% and 11.4%) and ‘Time to perceive the need for 
a new dose’ (RI= 9.0% and 8.2%). The ideal BA, for patients and physicians, should 
allow pain relief and an improvement of the functional capacity, with a low risk 
of adverse events, a long time prior to perceiving the need for a new dose and 
self-administration at home, when possible. ConClusions: Although efficacy and 
safety are key for patients with rheumatic diseases and rheumatologists to make a 
choice over a BA, the need for a low frequency of administration and the administra-
tion method also play an important role as preference attributes for BAs in Spain.
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objeCtives: Biological agents (BA) to treat rheumatic diseases are commonly 
administered by either the subcutaneous or the intravenous route. The objective 
of this study was to assess rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PA) Spanish patients’ preferences over BA considering the 
administration route. Methods: Observational, cross-sectional design. Participants 
were RA, AS and PA patients (diagnosed ≥ 2 years prior to study entry; currently 
or previously (≤ 1 year ago) receiving BA for a minimum of 1 year. Conjoint analy-
sis was performed to define preferences over 8 scenarios combining 4 attributes 
[‘Administration method’ (ADMINISTRATION), ‘Pain relief and improvement of the 
functional capacity’ (RELIEF), ‘Risk of adverse events’ (AE) and ‘Time until perceiv-
ing the need for a new dose’ related to the frequency of administration (TIME)]. 
Relative importance (RI) was calculated for patients on subcutaneous or intravenous 
administration, respectively. Results: A total of 488 patients [male= 50.9%; mean 
(SD) age= 50.6 (12.06) years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diag-
nosis= 12.6 (8.2) years; receiving currently BA= 98.2%] were included. The patients 
currently receiving subcutaneous (n= 305) or intravenous (n= 174) administration 
with BA gave highest importance to ‘RELIEF’ (45.4% and 46.7%) and ‘AE’ (28.2% and 
31.8%), followed by ‘ADMINISTRATION’ (19.7% and 10.2%) and ‘TIME’ (6.7% and 11.3%, 
respectively). Both groups of patients preferred to stay on the same route of adminis-
tration, either subcutaneous or intravenous, they had been on. Moreover all patients 
considered most crucial a longer time until perceiving the need for a new dose (8 
over 4 over 2 over 1 week). ConClusions: Spanish patients with rheumatic dis-
eases placed high importance on pain relief and risk of AEs as preference attributes 
for BAs. The frequency of administration (time until perceiving the need for a new 
dose) also plays a crucial role as all patients indicated their preference for lower vs. 
higher frequencies of BA administration.
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